Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100-mg in treatment-naïve HIV-infected patients

S. Lambert-Niclot*, N. Machouf, G. Peytavin, C. Soulie, M. Wirden, A. Simon, R. L. Murphy, C. Katlama, R. Thomas, V. Calvez, A. G. Marcelin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Objectives: Studies have shown the importance of having a high protein-binding-adjusted inhibitory quotient (IQ) for protease inhibitors (PIs) boosted with ritonavir. The objective of this study was to explore the virological response when combination atazanavir/ritonavir was administered to treatment-naïve patients.Methods: Protein-binding-adjusted IQs were calculated in 100 treatment-naïve patients initiating therapy with atazanavir 300 mg/ritonavir 100 mg plus two nucleoside reverse transcriptase inhibitors.Results: The median atazanavir trough level was 635 ng/mL [interquartile range (IQR) 342-1000] and the median atazanavir protein-binding-adjusted IQ was 45 (IQR 24-71). Eighty-four per cent of patients had a successful virological response, and those who failed did not develop resistance. The IQ for boosted atazanavir is high, resulting in rare treatment failure without resistance mutations. Conclusions: This study showed that the protein-binding-adjusted IQ of atazanavir is close to those measured for lopinavir and darunavir used once daily in first-line treatment. Finally the selection of resistance in the case of virological failure (plasma viral load >400 HIV-1 RNA copies/mL) to atazanavir/ritonavir used in first-line therapy seems uncommon, as it is for all boosted PIs.

Original languageEnglish (US)
Pages (from-to)666-669
Number of pages4
JournalHIV Medicine
Volume11
Issue number10
DOIs
StatePublished - Nov 2010

Keywords

  • Atazanavir
  • Inhibitory quotient
  • Protein binding
  • Resistance

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100-mg in treatment-naïve HIV-infected patients'. Together they form a unique fingerprint.

Cite this